Alliance Presents Final Results From Phase III CABINET Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors at ESMO 2024 and Published in New England Journal of Medicine

Final results from CABINET (Alliance A021602), a phase III trial evaluating cabozantinib compared with placebo in two cohorts of patients with previously treated neuroendocrine tumors: one cohort of patients with advanced pancreatic neuroendocrine tumors (pNET) and a second cohort of patients with advanced extra-pancreatic NET (epNET) were recently presented at ESMO 2024. The study met the primary objective for each cohort, demonstrating that cabozantinib provided dramatic improvements in med


UPCOMING MEETINGS

2024 Fall Hybrid Group Meeting
- October 30-November 1 | Schedule | Register

2025 Spring Hybrid Group Meeting
- April 30-May 3


All meetings are open to all
Alliance members.
 

ALLIANCE ON SOCIAL

FROM THE NCI